文献速递甲状腺疾病

分化型甲状腺癌放射性碘治疗外照射剂量率衰减规律与个体化管理研究

Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management.
PubMed 文献 · Thyroid · 2018-12-31

该研究纳入231例接受3.7 GBq(100 mCi)131I治疗的分化型甲状腺癌患者,通过测量给药后0至72小时距体表1米处的外照射剂量率(EDR)建立时间-EDR曲线。EDR衰减符合双指数衰减模型,截止值设为23.3 μSv/h,据此开发的预测软件预测值与实测值无统计学差异(p>0.05)。24小时摄碘率、131I全身扫描残留甲状腺分级、血游离三碘甲状腺原氨酸和游离甲状腺素是影响EDR下降的主要因素。

要点

  • EDR衰减符合双指数模型,截止值23.3 μSv/h,预测软件与实测无差异。
  • 24小时摄碘率、全身扫描残留甲状腺分级、FT3和FT4影响EDR下降。
  • 个体化预测安全出院时间有助于科学出院规划和辐射防护。

核心结论

  • 建立了有效便捷的方法来测量和预测个体化安全出院时间,有助于科学出院规划、合理利用医疗资源和改善个体化管理及公共辐射防护。

研究设计与样本

  • 研究纳入231例接受131I治疗的分化型甲状腺癌患者,均接受3.7 GBq(100 mCi)131I治疗。
  • 通过测量口服131I后0至72小时距体表1米处的外照射剂量率(EDR)估算残留体放射性,建立时间-EDR曲线。
  • 开发软件纳入40至60小时之间的六个时间点,预测患者剂量当量达到国家安全标准的时间。

主要发现

  • 患者EDR衰减规律可用双指数衰减模型描述,截止值设为23.3 μSv/h。
  • 预测值与实际测量值之间无统计学差异(p>0.05)。
  • 血清甲状腺球蛋白、总三碘甲状腺原氨酸、总甲状腺素、游离三碘甲状腺原氨酸、游离甲状腺素、促甲状腺激素、甲状腺2小时和24小时摄碘率、99mTc-高锝酸盐甲状腺扫描评分、131I全身扫描评分、超声扫描评分和胃肠道残留与衰减速度相关。
  • 多元线性回归分析发现24小时摄碘率(X1)、131I全身扫描残留甲状腺分级(X2)、血游离三碘甲状腺原氨酸(X3)和游离甲状腺素(X4)主要影响EDR下降,回归方程为Ŷ = 2.091X1 + 6.370X2 + 4.529X3 + 2.466X4 - 8.614(F=44.03,p<0.01)。

关键数值与推荐

  • EDR衰减截止值设为23.3 μSv/h。
  • 预测软件纳入40至60小时之间的六个时间点。
  • 回归方程:Ŷ = 2.091X1 + 6.370X2 + 4.529X3 + 2.466X4 - 8.614(F=44.03,p<0.01)。

临床怎么用

  • 可利用预测软件个体化预测患者达到国家安全标准的时间,优化出院计划。
  • 关注24小时摄碘率、全身扫描残留甲状腺分级、FT3和FT4等影响EDR衰减的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapy with radioactive iodine (131I) is a well established treatment method for postsurgical differentiated thyroid carcinoma (DTC). A fixed discharge time is generally set, regardless of individual differences in residual body radioactivity (RBA). This study aimed to investigate the RBA of each patient to find the attenuation law and to identify underlying factors in order to predict the time point for a safe, scientifically sound discharge plan. METHODS: A total of 231 DTC patients undergoing 131I treatment were all treated with 3.7 GBq (100 mCi) of 131I. RBA was estimated by measuring the external body dose rate (EDR) at a distance of 1 m from the body surface between 0 and 72 hours after oral administration of 131I. Data from each patient were used to establish a time-EDR value (h-μSv/h) curve. Software was developed to predict the time when a patient's dose equivalent meets the national safety standard by including six time points between 40 and 60 hours. Several factors that might affect that time were analyzed. RESULTS: The EDR attenuation law in patients could be described with a double exponential decay model, and the cutoff value was set as 23.3 μSv/h, upon which the predictive software was developed. Student's t-test showed there was no statistical difference between predicted values and the actual measured values (p > 0.05). Correlation analysis found that serum thyroglobulin, total triiodothyronine, total thyroxine, free triiodothyronine, free thyroxine, thyrotropin, 2- and 24-hour iodine uptake rate of the thyroid, scores of 99mTc-pertechnetate thyroid scan, scores of 131I whole-body scan, scores of ultrasound scan, and gastrointestinal residues were associated with attenuation speed. A further multiple linear regression analysis found that 24-hour iodine uptake (X1), residual thyroid grading by 131I whole-body scan (X2), blood free triiodothyronine (X3) and free thyroxine (X4) predominantly influenced the decline of the EDR. The regression equation was Ŷ = 2.091X1 + 6.370X2 + 4.529X3 + 2.466X4 - 8.614 (F = 44.03, p < 0.01). CONCLUSIONS: An effective and convenient method was created to measure and predict the individual safety time for discharge. This could play a significant role not only for scientific hospital discharge planning, rational use of medical resources, and better individualized management, but also in public radiation protection.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Li P, Zhang A, Liu Y, et al. Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management. Thyroid. 2018. PMID: 30351248. doi:10.1089/thy.2017.0570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。